Modality
siRNA
MOA
PI3Ki
Target
TROP-2
Pathway
PI3K/AKT
MDS
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
Sep 2021
Phase 1Current
NCT07079305
832 pts·MDS
2021-09→TBD·Active
832 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1/2
Active
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07079305 | Phase 1/2 | MDS | Active | 832 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 |